PopulationPostmenopausal women without underlying disease; mean age 55 years
Sample17 enrolled; 16 completed after one withdrawal for persistent mild headache
InterventionPure NMN 300 mg/day orally for 8 weeks
EndpointsBody measurements and basal metabolic rate; Blood pressure and grip strength; Glycation autofluorescence; Blood chemistry and hormones; Blood SIRT1 mRNA, NMN, NAD and nicotinamide; Immune-cell subsets; Skin, sleep, fatigue and other subjective diary measures
What the publication reported
This exploratory single-arm study gave 300 mg/day NMN to 17 postmenopausal women for eight weeks and compared biomarkers before and after supplementation. Sixteen participants completed the study.
Several laboratory, metabolic, immune, glycation, and subjective measures changed over time, including NAD-related metabolites. One participant withdrew after persistent mild headache.
Because there was no placebo or untreated control group and many endpoints were tested, the study cannot establish that NMN caused the observed changes. It is best treated as early human exploratory evidence.
Key findings
Nicotinamide and NAD-related measures changed over the eight-week intervention.
The report described statistically significant changes in adiponectin, BMI, glycation autofluorescence, HbA1c, HDL-C and several other biomarkers.
Participants reported subjective changes in skin, sleep and fatigue measures.
One of 17 participants discontinued at four weeks because of persistent mild headache.
No major laboratory safety problem was reported among the 16 completers.
What it cannot establish
No placebo or untreated comparator was included.
Small sample of postmenopausal women only.
Many biomarkers and subjective endpoints were tested, increasing multiplicity concerns.
One participant withdrew because of persistent mild headache.
Funding, competing-interest and trial-registration statements were not stated in the publication information verified for this record.
HealthspanX claim boundary: This record does not establish that NMN caused the observed biomarker or subjective changes and does not support anti-aging, disease-treatment, longevity, or product-equivalence claims.
